Acute Urinary Retention News and Research RSS Feed - Acute Urinary Retention News and Research

Urinary retention is the inability to empty the bladder. With chronic urinary retention, you may be able to urinate, but you have trouble starting a stream or emptying your bladder completely. You may urinate frequently; you may feel an urgent need to urinate but have little success when you get to the toilet; or you may feel you still have to go after you’ve finished urinating. With acute urinary retention, you can’t urinate at all, even though you have a full bladder. Acute urinary retention is a medical emergency requiring prompt action. Chronic urinary retention may not seem life threatening, but it can lead to serious problems and should also receive attention from a health professional.

Antimuscarinics plus α-blockers ‘recommended for male LUTS’

Antimuscarinics “could and should” be used in the pharmacological treatment of men with lower urinary tract symptoms caused by benign prostatic hyperplasia or bladder outlet obstruction, say the authors of a meta-analysis published in Urology. [More]

Mirabegron reduces frequency of incontinence episodes in phase III trial

In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group. [More]

Thulium vapoenucleation well-tolerated for treating benign prostate obstruction

Treating benign prostate obstruction with thulium vapoenucleation of the prostate is well-tolerated and effective and leads to a low incidence of perioperative complications, according to recent study findings. [More]
New embolization procedure may bring hope to men with enlarged prostate

New embolization procedure may bring hope to men with enlarged prostate

A new interventional radiology treatment, prostatic artery embolization, may bring hope to men with debilitating symptoms caused by an enlarged prostate, say the group of researchers who pioneered its use. [More]

Treatment for acute urinary retention due to BPH varies among countries

Men who experience a sudden inability to pass urine because of a non-cancerous enlarged prostate are hospitalised and treated differently depending on where they live, according to an international study published online by the urology journal BJUI. [More]
FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older. [More]

FDA issues Complete Response letter for Avodart sNDA for reduction of prostate cancer risk

GlaxoSmithKline (GSK) today announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at increased risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA). [More]
Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

Recordati and Nymox Pharmaceutical Corporation announced today the signing of a European licensing agreement for the development and commercialization of NX-1207, Nymox's Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH). [More]

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program. [More]

Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). [More]

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S. [More]

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date. [More]

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center. [More]

Tru-flo urinary catheter valve from ProtekMed

ProtekMed has launched the Tru-flo(TM) urinary catheter valve, an innovative and economical alternative to the standard tube and bag system prescribed by most urologists today. [More]

AbbeyMoor Medical's The Spanner temporary prostatic stent insertion procedure receives Category I CPT code

AbbeyMoor Medical Inc. announced today they have been granted a Category I CPT code by the American Medical Association (AMA) for The Spanner(TM) temporary prostatic stent insertion procedure. This important action, effective in January 2010, upgrades The Spanner from a Category III emerging technology procedure code to a Category I procedure code for established procedures. [More]

Long-term complications for children fed with melamine contaminated products

Children with a history of consuming melamine-contaminated milk powder are at an increased risk of developing kidney stones and other urological complications. [More]

Nymox nears completion of benign prostatic hyperplasia drug trial

Nymox Pharmaceutical Corporation has announced that the Company's latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion. [More]
Urinary complications in men over 45

Urinary complications in men over 45

As many as one in four men admitted to hospital with acute urinary retention will die within a year, finds a study published on bmj.com. [More]

TUNA therapy results in significantly reduced erectile dysfunction

Comparing five-year results of Medtronic TUNA® Therapy (transurethral needle ablation) to surgery for 121 men in their mid-60s with lower urinary tract symptoms caused by an enlarged prostate, a team of urologists found that “for appropriately selected patients with bothersome voiding symptoms, TUNA is an attractive treatment option.” [More]
Sexual Dysfunction in benign prostatic hyperplasia (BPH) twice as high as physicians estimate

Sexual Dysfunction in benign prostatic hyperplasia (BPH) twice as high as physicians estimate

The incidence of sexual dysfunction in patients suffering from Benign Prostatic Hyperplasia (BPH) -- or enlarged prostate -- is nearly twice as high as treating physicians believe shows a new survey from the American Foundation for Urologic Diseases (AFUD) presented today at the American Urological Association annual meeting. [More]